---
title: Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic
  cancer - Results of a phase 1b clinical trial
date: '2024-02-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38401449/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240225170529&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In this phase 1b clinical trial, the MTD of gemcitabine/nab-paclitaxel
  (1000 mg/m² / 125 mg/m²) and afatinib (30 mg) was established. In a cohort of 11
  patients, the combination showed an acceptable safety ...'
disable_comments: true
---
CONCLUSIONS: In this phase 1b clinical trial, the MTD of gemcitabine/nab-paclitaxel (1000 mg/m² / 125 mg/m²) and afatinib (30 mg) was established. In a cohort of 11 patients, the combination showed an acceptable safety ...